M. Draguetbrughmans
Université catholique de Louvain
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Draguetbrughmans.
Drug Development and Industrial Pharmacy | 1986
Chantal Lefebvre; Am. Guyothermann; M. Draguetbrughmans; Raymond Bouche; J. C. Guyot
Carbamazepine is a potent anticonvulsivant, but, irregular plasma levels are noticed. The variability of therapeutic efficiency can be attributed to interindividual sensibility, chronobiologic effect, but also to rates of dissolution which can differ when polymorphs are induced by technologic operations.Several crystalline forms of Carbamazepine have been characterized. As for us, we have studied three crystalline modifications which can be found in commercialized galenic forms: the most usual beta form, the alpha form and the dihydrate.The aim of this work was to investigate:- the behaviour of these three crystalline forms during compression- the possibility of crystalline structural changes under grinding and tabletting conditions. Indeed, polymorphous transformations may occur during technologic operations such as grinding or compression owing to the increase of internal energy.Grinding was performed in a ball mill for 15 and 60 minutes. Compression was carried out using an instrumented single punch ma...
Journal of Pharmaceutical and Biomedical Analysis | 1985
M. Draguetbrughmans; Raymond Bouche; Chantal Lefebvre
In a study of variations in the physicochemical properties of digoxin powder from several commercial sources, recrystallizations of digoxin were performed under several conditions. Polymorphs were not obtained whereas a pure amorphous form was formed under certain conditions. The amorphous form was more soluble and more stable under compression than was the crystalline form; nevertheless in contact with water it crystallized quickly. Traces of the crystalline form reduced the dissolution rate and stability of the amorphous form. Variations in the thermal behaviour of commercial samples can be explained by the presence of variable proportions of the amorphous form and also by thermal decomposition that varies from one sample to another and generally occurs at 160 degrees C and above.
Pharmaceutica Acta Helvetiae | 1987
Chantal Lefebvre; Am. Guyothermann; M. Draguetbrughmans; Raymond Bouche
Journal of Thermal Analysis and Calorimetry | 1981
M. Draguetbrughmans; Raymond Bouche
Bulletin des Sociétés Chimiques Belges | 2010
M. Vanmeerssche; Jean-Paul Declercq; Gabriel Germain; Raymond Bouche; M. Draguetbrughmans
Pharmaceutica Acta Helvetiae | 1984
M. Draguetbrughmans; Chantal Lefebvre; Am. Guyothermann; Raymond Bouche
Journal of Pharmaceutical Sciences | 1984
M. Azibi; M. Draguetbrughmans; Raymond Bouche
Pharmaceutica Acta Helvetiae | 1981
M. Azibi; M. Draguetbrughmans; Raymond Bouche
Bulletin des Sociétés Chimiques Belges | 2010
Bernard Tinant; Gabriel Germain; Jean-Paul Declercq; M. Van Meerssche; M. Azibi; M. Draguetbrughmans; Raymond Bouche
Pharmaceutica Acta Helvetiae | 1981
M. Azibi; M. Draguetbrughmans; Raymond Bouche